Treatment with an oral fluoropyrimidine, S-1, plus cisplatin in patients who failed postoperative gemcitabine treatment for pancreatic cancer: a pilot ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2007-08-20

AUTHORS

Akira Togawa, Hideyuki Yoshitomi, Hiroshi Ito, Fumio Kimura, Hiroaki Shimizu, Masayuki Ohtsuka, Hiroyuki Yoshidome, Atsushi Kato, Shigeaki Sawada, Masaru Miyazaki

ABSTRACT

BackgroundThis study set out to evaluate, in patients with gemcitabine-resistant pancreatic cancer, the response rate and toxicity of S-1 plus cisplatin (CDDP).MethodsSeventeen patients with histologically diagnosed invasive ductal pancreatic cancer were enrolled in this study. All patients had growing recurrent pancreas cancer despite the administration of gemcitabine. Thirteen patients underwent pancreatectomy, and 2 underwent choledochojejunostomy and gastrojejunostomy without pancreatectomy. S-1 (80 mg/m2 per day) was orally administered for 21 consecutive days, followed by a 14-day rest period. CDDP (40 mg/m2) in 500 ml saline was administered by intravenous drip on day 8. This schedule was repeated every 5 weeks until the occurrence of disease progression, unacceptable toxicities, or the patient's refusal to continue.ResultsFive (29.4%) patients achieved a partial response and 2 (11.8%) had stable disease. In 5 of 15 patients (33.3%) who had elevated serum carbohydrate antigen (CA)19-9 levels at the start of treatment the CA19-9 was reduced by more than 50%. The median survival time was 10 months (range, 20 months), with 63.7% and 31.9% of patients alive at 6 and 12 months, respectively. Major adverse reactions in the 15 patients included gastrointestinal toxicities of grade 1 or 2. Only one patient (5.9%) developed grade 3 leucopenia.ConclusionS-1 with CDDP has a promising effect against gemcitabine-resistant pancreatic cancer, with easily manageable toxicities. Further investigation of this regimen is warranted in patients with pancreatic cancer, especially in comparison with gemcitabine. More... »

PAGES

268-273

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10147-007-0674-x

DOI

http://dx.doi.org/10.1007/s10147-007-0674-x

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1025035673

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/17701005


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Administration, Oral", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cisplatin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Deoxycytidine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Combinations", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Resistance, Neoplasm", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Oxonic Acid", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pancreatic Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pilot Projects", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tegafur", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Failure", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of General Surgery, Chiba University Graduate School of Medicine, Inohana 1-8-1, Chuo-ku, 260-0856, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of General Surgery, Chiba University Graduate School of Medicine, Inohana 1-8-1, Chuo-ku, 260-0856, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Togawa", 
        "givenName": "Akira", 
        "id": "sg:person.0660326574.22", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0660326574.22"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of General Surgery, Chiba University Graduate School of Medicine, Inohana 1-8-1, Chuo-ku, 260-0856, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of General Surgery, Chiba University Graduate School of Medicine, Inohana 1-8-1, Chuo-ku, 260-0856, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yoshitomi", 
        "givenName": "Hideyuki", 
        "id": "sg:person.01245062664.63", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01245062664.63"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of General Surgery, Chiba University Graduate School of Medicine, Inohana 1-8-1, Chuo-ku, 260-0856, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of General Surgery, Chiba University Graduate School of Medicine, Inohana 1-8-1, Chuo-ku, 260-0856, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ito", 
        "givenName": "Hiroshi", 
        "id": "sg:person.013440705734.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013440705734.23"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of General Surgery, Chiba University Graduate School of Medicine, Inohana 1-8-1, Chuo-ku, 260-0856, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of General Surgery, Chiba University Graduate School of Medicine, Inohana 1-8-1, Chuo-ku, 260-0856, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kimura", 
        "givenName": "Fumio", 
        "id": "sg:person.01127754745.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01127754745.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of General Surgery, Chiba University Graduate School of Medicine, Inohana 1-8-1, Chuo-ku, 260-0856, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of General Surgery, Chiba University Graduate School of Medicine, Inohana 1-8-1, Chuo-ku, 260-0856, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shimizu", 
        "givenName": "Hiroaki", 
        "id": "sg:person.01103413111.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01103413111.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of General Surgery, Chiba University Graduate School of Medicine, Inohana 1-8-1, Chuo-ku, 260-0856, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of General Surgery, Chiba University Graduate School of Medicine, Inohana 1-8-1, Chuo-ku, 260-0856, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ohtsuka", 
        "givenName": "Masayuki", 
        "id": "sg:person.0653527253.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653527253.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of General Surgery, Chiba University Graduate School of Medicine, Inohana 1-8-1, Chuo-ku, 260-0856, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of General Surgery, Chiba University Graduate School of Medicine, Inohana 1-8-1, Chuo-ku, 260-0856, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yoshidome", 
        "givenName": "Hiroyuki", 
        "id": "sg:person.016423226454.74", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016423226454.74"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of General Surgery, Chiba University Graduate School of Medicine, Inohana 1-8-1, Chuo-ku, 260-0856, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of General Surgery, Chiba University Graduate School of Medicine, Inohana 1-8-1, Chuo-ku, 260-0856, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kato", 
        "givenName": "Atsushi", 
        "id": "sg:person.01354163205.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01354163205.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of General Surgery, Chiba University Graduate School of Medicine, Inohana 1-8-1, Chuo-ku, 260-0856, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of General Surgery, Chiba University Graduate School of Medicine, Inohana 1-8-1, Chuo-ku, 260-0856, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sawada", 
        "givenName": "Shigeaki", 
        "id": "sg:person.01254756155.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01254756155.13"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of General Surgery, Chiba University Graduate School of Medicine, Inohana 1-8-1, Chuo-ku, 260-0856, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of General Surgery, Chiba University Graduate School of Medicine, Inohana 1-8-1, Chuo-ku, 260-0856, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Miyazaki", 
        "givenName": "Masaru", 
        "id": "sg:person.0773025611.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0773025611.35"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/sj.bjc.6601413", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020677763", 
          "https://doi.org/10.1038/sj.bjc.6601413"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2007-08-20", 
    "datePublishedReg": "2007-08-20", 
    "description": "BackgroundThis study set out to evaluate, in patients with gemcitabine-resistant pancreatic cancer, the response rate and toxicity of S-1 plus cisplatin (CDDP).MethodsSeventeen patients with histologically diagnosed invasive ductal pancreatic cancer were enrolled in this study. All patients had growing recurrent pancreas cancer despite the administration of gemcitabine. Thirteen patients underwent pancreatectomy, and 2 underwent choledochojejunostomy and gastrojejunostomy without pancreatectomy. S-1 (80\u2009mg/m2 per day) was orally administered for 21 consecutive days, followed by a 14-day rest period. CDDP (40\u2009mg/m2) in 500\u2009ml saline was administered by intravenous drip on day 8. This schedule was repeated every 5 weeks until the occurrence of disease progression, unacceptable toxicities, or the patient's refusal to continue.ResultsFive (29.4%) patients achieved a partial response and 2 (11.8%) had stable disease. In 5 of 15 patients (33.3%) who had elevated serum carbohydrate antigen (CA)19-9 levels at the start of treatment the CA19-9 was reduced by more than 50%. The median survival time was 10 months (range, 20 months), with 63.7% and 31.9% of patients alive at 6 and 12 months, respectively. Major adverse reactions in the 15 patients included gastrointestinal toxicities of grade 1 or 2. Only one patient (5.9%) developed grade 3 leucopenia.ConclusionS-1 with CDDP has a promising effect against gemcitabine-resistant pancreatic cancer, with easily manageable toxicities. Further investigation of this regimen is warranted in patients with pancreatic cancer, especially in comparison with gemcitabine.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s10147-007-0674-x", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1312225", 
        "issn": [
          "1341-9625", 
          "1437-7772"
        ], 
        "name": "International Journal of Clinical Oncology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "12"
      }
    ], 
    "keywords": [
      "gemcitabine-resistant pancreatic cancer", 
      "pancreatic cancer", 
      "invasive ductal pancreatic cancer", 
      "serum carbohydrate antigen", 
      "grade 3 leucopenia", 
      "major adverse reactions", 
      "ductal pancreatic cancer", 
      "median survival time", 
      "start of treatment", 
      "administration of gemcitabine", 
      "underwent choledochojejunostomy", 
      "stable disease", 
      "manageable toxicity", 
      "oral fluoropyrimidine", 
      "unacceptable toxicity", 
      "gastrointestinal toxicity", 
      "partial response", 
      "MethodsSeventeen patients", 
      "ResultsFive patients", 
      "pancreas cancer", 
      "intravenous drip", 
      "patient refusal", 
      "CA19-9", 
      "gemcitabine treatment", 
      "adverse reactions", 
      "disease progression", 
      "survival time", 
      "BackgroundThis study", 
      "patients", 
      "response rate", 
      "day 8", 
      "carbohydrate antigens", 
      "grade 1", 
      "cancer", 
      "consecutive days", 
      "pilot study", 
      "promising effects", 
      "pancreatectomy", 
      "gemcitabine", 
      "rest period", 
      "CDDP", 
      "treatment", 
      "further investigation", 
      "toxicity", 
      "cisplatin", 
      "months", 
      "choledochojejunostomy", 
      "gastrojejunostomy", 
      "leucopenia", 
      "regimen", 
      "fluoropyrimidines", 
      "antigen", 
      "disease", 
      "administration", 
      "progression", 
      "saline", 
      "weeks", 
      "study", 
      "refusal", 
      "days", 
      "response", 
      "period", 
      "drip", 
      "levels", 
      "schedule", 
      "start", 
      "occurrence", 
      "rate", 
      "effect", 
      "time", 
      "investigation", 
      "comparison", 
      "reaction"
    ], 
    "name": "Treatment with an oral fluoropyrimidine, S-1, plus cisplatin in patients who failed postoperative gemcitabine treatment for pancreatic cancer: a pilot study", 
    "pagination": "268-273", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1025035673"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10147-007-0674-x"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "17701005"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10147-007-0674-x", 
      "https://app.dimensions.ai/details/publication/pub.1025035673"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T15:51", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_441.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s10147-007-0674-x"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10147-007-0674-x'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10147-007-0674-x'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10147-007-0674-x'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10147-007-0674-x'


 

This table displays all metadata directly associated to this object as RDF triples.

273 TRIPLES      21 PREDICATES      117 URIs      108 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10147-007-0674-x schema:about N04e3d612a5a84f588a65a73012248a8c
2 N0ef8bdceb5224e53a595c40db07f0ac6
3 N39d2a5ffb6c24f7f9b5004055a0e0eb8
4 N52c43027e9c349f396909faff8b4bd5f
5 N658164d8fef24830ac77980e19e84963
6 N6a2835ec0410480bbac8ad0e276cdac2
7 N7bcd39c646b54122b0873e74dd9093e5
8 N8b4abf608cd2449296cf4187b1f6032f
9 Na46a156c1254405a87f0325e3bd53d7f
10 Na7eda40458ca4ce58381751019f8344e
11 Nb2c1d6080b7943f4bbd5d7b2bef135fb
12 Nb46f525c5065481e9146a406a2e78944
13 Nbf62c3fc524f4aec85fbeabaa9360d1c
14 Nd62d93698a7e43bf957da42b914e44fe
15 Nd6d56bdf625d4789811587fe50063209
16 Ne46c94ba8b3b4c7a8e58d05b8e9f2d09
17 Nefbf0fd380f241e69ad5166df021c93c
18 Nfd9edac92ed04e3b9d1ccb6c1bbf0345
19 anzsrc-for:11
20 anzsrc-for:1112
21 schema:author Na72515ebf2884d379876cd4e4fac61bd
22 schema:citation sg:pub.10.1038/sj.bjc.6601413
23 schema:datePublished 2007-08-20
24 schema:datePublishedReg 2007-08-20
25 schema:description BackgroundThis study set out to evaluate, in patients with gemcitabine-resistant pancreatic cancer, the response rate and toxicity of S-1 plus cisplatin (CDDP).MethodsSeventeen patients with histologically diagnosed invasive ductal pancreatic cancer were enrolled in this study. All patients had growing recurrent pancreas cancer despite the administration of gemcitabine. Thirteen patients underwent pancreatectomy, and 2 underwent choledochojejunostomy and gastrojejunostomy without pancreatectomy. S-1 (80 mg/m2 per day) was orally administered for 21 consecutive days, followed by a 14-day rest period. CDDP (40 mg/m2) in 500 ml saline was administered by intravenous drip on day 8. This schedule was repeated every 5 weeks until the occurrence of disease progression, unacceptable toxicities, or the patient's refusal to continue.ResultsFive (29.4%) patients achieved a partial response and 2 (11.8%) had stable disease. In 5 of 15 patients (33.3%) who had elevated serum carbohydrate antigen (CA)19-9 levels at the start of treatment the CA19-9 was reduced by more than 50%. The median survival time was 10 months (range, 20 months), with 63.7% and 31.9% of patients alive at 6 and 12 months, respectively. Major adverse reactions in the 15 patients included gastrointestinal toxicities of grade 1 or 2. Only one patient (5.9%) developed grade 3 leucopenia.ConclusionS-1 with CDDP has a promising effect against gemcitabine-resistant pancreatic cancer, with easily manageable toxicities. Further investigation of this regimen is warranted in patients with pancreatic cancer, especially in comparison with gemcitabine.
26 schema:genre article
27 schema:isAccessibleForFree false
28 schema:isPartOf N59e24f4e7948440684d8a5f15e61896d
29 N9a42db9efdb74f7db35c2596e206043b
30 sg:journal.1312225
31 schema:keywords BackgroundThis study
32 CA19-9
33 CDDP
34 MethodsSeventeen patients
35 ResultsFive patients
36 administration
37 administration of gemcitabine
38 adverse reactions
39 antigen
40 cancer
41 carbohydrate antigens
42 choledochojejunostomy
43 cisplatin
44 comparison
45 consecutive days
46 day 8
47 days
48 disease
49 disease progression
50 drip
51 ductal pancreatic cancer
52 effect
53 fluoropyrimidines
54 further investigation
55 gastrointestinal toxicity
56 gastrojejunostomy
57 gemcitabine
58 gemcitabine treatment
59 gemcitabine-resistant pancreatic cancer
60 grade 1
61 grade 3 leucopenia
62 intravenous drip
63 invasive ductal pancreatic cancer
64 investigation
65 leucopenia
66 levels
67 major adverse reactions
68 manageable toxicity
69 median survival time
70 months
71 occurrence
72 oral fluoropyrimidine
73 pancreas cancer
74 pancreatectomy
75 pancreatic cancer
76 partial response
77 patient refusal
78 patients
79 period
80 pilot study
81 progression
82 promising effects
83 rate
84 reaction
85 refusal
86 regimen
87 response
88 response rate
89 rest period
90 saline
91 schedule
92 serum carbohydrate antigen
93 stable disease
94 start
95 start of treatment
96 study
97 survival time
98 time
99 toxicity
100 treatment
101 unacceptable toxicity
102 underwent choledochojejunostomy
103 weeks
104 schema:name Treatment with an oral fluoropyrimidine, S-1, plus cisplatin in patients who failed postoperative gemcitabine treatment for pancreatic cancer: a pilot study
105 schema:pagination 268-273
106 schema:productId Nbe7ad0b7ea68459292e956c87b08a922
107 Nd93a11c9123e48c3a61973d35d6d90f5
108 Nfeab824d53f44bacabe65b9317faad84
109 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025035673
110 https://doi.org/10.1007/s10147-007-0674-x
111 schema:sdDatePublished 2022-09-02T15:51
112 schema:sdLicense https://scigraph.springernature.com/explorer/license/
113 schema:sdPublisher Nf121ea51e51c4ca484e719d39a2cb124
114 schema:url https://doi.org/10.1007/s10147-007-0674-x
115 sgo:license sg:explorer/license/
116 sgo:sdDataset articles
117 rdf:type schema:ScholarlyArticle
118 N04e3d612a5a84f588a65a73012248a8c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Cisplatin
120 rdf:type schema:DefinedTerm
121 N0ef8bdceb5224e53a595c40db07f0ac6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Aged
123 rdf:type schema:DefinedTerm
124 N106dffab608b4ed7b38331aeb26fa0fa rdf:first sg:person.016423226454.74
125 rdf:rest Nfe6933dba6cf426eb54ad38d9a13e5ea
126 N3410b247e3a7402a91b1f1665174a64f rdf:first sg:person.0773025611.35
127 rdf:rest rdf:nil
128 N36d80d26fac34ff7a17d3d4f061637da rdf:first sg:person.01103413111.45
129 rdf:rest Nf947f941a36d4618acc53a31760eb091
130 N39d2a5ffb6c24f7f9b5004055a0e0eb8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Survival Analysis
132 rdf:type schema:DefinedTerm
133 N52c43027e9c349f396909faff8b4bd5f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Drug Resistance, Neoplasm
135 rdf:type schema:DefinedTerm
136 N59e24f4e7948440684d8a5f15e61896d schema:issueNumber 4
137 rdf:type schema:PublicationIssue
138 N658164d8fef24830ac77980e19e84963 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Pancreatic Neoplasms
140 rdf:type schema:DefinedTerm
141 N6a2835ec0410480bbac8ad0e276cdac2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Oxonic Acid
143 rdf:type schema:DefinedTerm
144 N7bcd39c646b54122b0873e74dd9093e5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Pilot Projects
146 rdf:type schema:DefinedTerm
147 N8b4abf608cd2449296cf4187b1f6032f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Middle Aged
149 rdf:type schema:DefinedTerm
150 N9a42db9efdb74f7db35c2596e206043b schema:volumeNumber 12
151 rdf:type schema:PublicationVolume
152 Na1684c155a884eeeb29a5040bbf6e800 rdf:first sg:person.01254756155.13
153 rdf:rest N3410b247e3a7402a91b1f1665174a64f
154 Na46a156c1254405a87f0325e3bd53d7f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Administration, Oral
156 rdf:type schema:DefinedTerm
157 Na72515ebf2884d379876cd4e4fac61bd rdf:first sg:person.0660326574.22
158 rdf:rest Ne13dd59ff69441069e5a8f5cce8d99cf
159 Na7eda40458ca4ce58381751019f8344e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Deoxycytidine
161 rdf:type schema:DefinedTerm
162 Nb2c1d6080b7943f4bbd5d7b2bef135fb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Drug Combinations
164 rdf:type schema:DefinedTerm
165 Nb46f525c5065481e9146a406a2e78944 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Tegafur
167 rdf:type schema:DefinedTerm
168 Nbe7ad0b7ea68459292e956c87b08a922 schema:name dimensions_id
169 schema:value pub.1025035673
170 rdf:type schema:PropertyValue
171 Nbf62c3fc524f4aec85fbeabaa9360d1c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Male
173 rdf:type schema:DefinedTerm
174 Nc11aceea698f49728109fccb3af071dc rdf:first sg:person.01127754745.32
175 rdf:rest N36d80d26fac34ff7a17d3d4f061637da
176 Nd62d93698a7e43bf957da42b914e44fe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Antineoplastic Combined Chemotherapy Protocols
178 rdf:type schema:DefinedTerm
179 Nd6d56bdf625d4789811587fe50063209 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Treatment Outcome
181 rdf:type schema:DefinedTerm
182 Nd93a11c9123e48c3a61973d35d6d90f5 schema:name doi
183 schema:value 10.1007/s10147-007-0674-x
184 rdf:type schema:PropertyValue
185 Ne12147c5037f4344a702e98646f76848 rdf:first sg:person.013440705734.23
186 rdf:rest Nc11aceea698f49728109fccb3af071dc
187 Ne13dd59ff69441069e5a8f5cce8d99cf rdf:first sg:person.01245062664.63
188 rdf:rest Ne12147c5037f4344a702e98646f76848
189 Ne46c94ba8b3b4c7a8e58d05b8e9f2d09 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
190 schema:name Treatment Failure
191 rdf:type schema:DefinedTerm
192 Nefbf0fd380f241e69ad5166df021c93c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
193 schema:name Humans
194 rdf:type schema:DefinedTerm
195 Nf121ea51e51c4ca484e719d39a2cb124 schema:name Springer Nature - SN SciGraph project
196 rdf:type schema:Organization
197 Nf947f941a36d4618acc53a31760eb091 rdf:first sg:person.0653527253.30
198 rdf:rest N106dffab608b4ed7b38331aeb26fa0fa
199 Nfd9edac92ed04e3b9d1ccb6c1bbf0345 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
200 schema:name Female
201 rdf:type schema:DefinedTerm
202 Nfe6933dba6cf426eb54ad38d9a13e5ea rdf:first sg:person.01354163205.16
203 rdf:rest Na1684c155a884eeeb29a5040bbf6e800
204 Nfeab824d53f44bacabe65b9317faad84 schema:name pubmed_id
205 schema:value 17701005
206 rdf:type schema:PropertyValue
207 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
208 schema:name Medical and Health Sciences
209 rdf:type schema:DefinedTerm
210 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
211 schema:name Oncology and Carcinogenesis
212 rdf:type schema:DefinedTerm
213 sg:journal.1312225 schema:issn 1341-9625
214 1437-7772
215 schema:name International Journal of Clinical Oncology
216 schema:publisher Springer Nature
217 rdf:type schema:Periodical
218 sg:person.01103413111.45 schema:affiliation grid-institutes:grid.136304.3
219 schema:familyName Shimizu
220 schema:givenName Hiroaki
221 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01103413111.45
222 rdf:type schema:Person
223 sg:person.01127754745.32 schema:affiliation grid-institutes:grid.136304.3
224 schema:familyName Kimura
225 schema:givenName Fumio
226 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01127754745.32
227 rdf:type schema:Person
228 sg:person.01245062664.63 schema:affiliation grid-institutes:grid.136304.3
229 schema:familyName Yoshitomi
230 schema:givenName Hideyuki
231 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01245062664.63
232 rdf:type schema:Person
233 sg:person.01254756155.13 schema:affiliation grid-institutes:grid.136304.3
234 schema:familyName Sawada
235 schema:givenName Shigeaki
236 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01254756155.13
237 rdf:type schema:Person
238 sg:person.013440705734.23 schema:affiliation grid-institutes:grid.136304.3
239 schema:familyName Ito
240 schema:givenName Hiroshi
241 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013440705734.23
242 rdf:type schema:Person
243 sg:person.01354163205.16 schema:affiliation grid-institutes:grid.136304.3
244 schema:familyName Kato
245 schema:givenName Atsushi
246 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01354163205.16
247 rdf:type schema:Person
248 sg:person.016423226454.74 schema:affiliation grid-institutes:grid.136304.3
249 schema:familyName Yoshidome
250 schema:givenName Hiroyuki
251 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016423226454.74
252 rdf:type schema:Person
253 sg:person.0653527253.30 schema:affiliation grid-institutes:grid.136304.3
254 schema:familyName Ohtsuka
255 schema:givenName Masayuki
256 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653527253.30
257 rdf:type schema:Person
258 sg:person.0660326574.22 schema:affiliation grid-institutes:grid.136304.3
259 schema:familyName Togawa
260 schema:givenName Akira
261 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0660326574.22
262 rdf:type schema:Person
263 sg:person.0773025611.35 schema:affiliation grid-institutes:grid.136304.3
264 schema:familyName Miyazaki
265 schema:givenName Masaru
266 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0773025611.35
267 rdf:type schema:Person
268 sg:pub.10.1038/sj.bjc.6601413 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020677763
269 https://doi.org/10.1038/sj.bjc.6601413
270 rdf:type schema:CreativeWork
271 grid-institutes:grid.136304.3 schema:alternateName Department of General Surgery, Chiba University Graduate School of Medicine, Inohana 1-8-1, Chuo-ku, 260-0856, Chiba, Japan
272 schema:name Department of General Surgery, Chiba University Graduate School of Medicine, Inohana 1-8-1, Chuo-ku, 260-0856, Chiba, Japan
273 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...